Boston Scientific Corporation $BSX Stake Boosted by UMB Bank n.a.

Key Points

• UMB Bank n.a. increased its stake in Boston Scientific Corporation (NYSE:BSX) by 4.4% in the second quarter, now holding 75,214 shares valued at approximately $8.08 million.
• Insider transactions revealed that EVP Joseph Fitzgerald sold 50,000 shares for $5.27 million, resulting in a 21.9% decrease in his holdings.
• Boston Scientific reported a quarterly revenue of $5.06 billion, exceeding analysts' expectations, driven by a 22.8% year-over-year growth.

UMB Bank n.a. raised its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 75,214 shares of the medical equipment provider's stock after buying an additional 3,139 shares during the quarter. UMB Bank n.a.'s holdings in Boston Scientific were worth $8,079,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Brighton Jones LLC lifted its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares during the period. Bank Pictet & Cie Europe AG boosted its holdings in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after acquiring an additional 21,173 shares in the last quarter. State of Wyoming lifted its position in Boston Scientific by 119.5% in the 4th quarter. State of Wyoming now owns 2,660 shares of the medical equipment provider's stock valued at $238,000 after acquiring an additional 1,448 shares in the last quarter. Waverly Advisors LLC lifted its position in Boston Scientific by 24.2% during the fourth quarter. Waverly Advisors LLC now owns 11,174 shares of the medical equipment provider's stock valued at $998,000 after purchasing an additional 2,179 shares during the period. Finally, Novem Group purchased a new position in Boston Scientific in the fourth quarter worth about $220,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock valued at $18,397,457. Company insiders own 0.50% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on BSX shares. Robert W. Baird boosted their price target on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. UBS Group lifted their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Needham & Company LLC restated a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Friday. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $118.04.

Boston Scientific Stock Down 0.9%

Shares of BSX stock traded down $0.92 during mid-day trading on Monday, hitting $96.91. 11,012,552 shares of the stock traded hands, compared to its average volume of 7,720,951. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The stock has a market cap of $143.60 billion, a P/E ratio of 57.69, a P/E/G ratio of 2.36 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock's fifty day moving average is $104.40 and its two-hundred day moving average is $102.10.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the company earned $0.62 earnings per share. Boston Scientific's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.